A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

Protocol No

BIOATLA-BA3011-001

Phase

I/II

Summary

The purpose of this study is to learn about the safety and effectiveness of an experimental drug called Mecbotamab Vedotin (BA3011) on a variety of cancers that have tested positive for the AXL protein. This study is the first time the Mecbotamab Vedotin has been tested in humans.

Description

The purpose of this study is to learn about the safety and effectiveness of an experimental drug called Mecbotamab Vedotin (BA3011) on a variety of cancers that have tested positive for the AXL protein.

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL